ArticleClinical case reports2025
Case Report: Omadacycline in the Treatment of Community-Acquired Pneumonia in a Child With Multiple Antimicrobial Allergies.
Article in Clinical case reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Case Report: Omadacycline in the Treatment of Community-Acquired Pneumonia in a Child With Multiple Antimicrobial Allergies.Clinical case reports · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Omadacycline, a novel once-daily aminomethylcycline antibiotic agent, demonstrates efficacy against prevalent pathogens responsible for community-acquired pneumonia (CAP) in adults. However, the safety and efficacy of omadacycline in younger children have not yet been established. This case report presents a 4-year-old girl with a mixed infection of CAP who exhibited hypersensitivity to multiple antimicrobial agents (piperacillin-tazobactam, ceftazidime, fosfomycin, meropenem, and levofloxacin), was treated with omadacycline followed by doxycycline, and underwent bronchoscopy with bronchoalveolar lavage. The child's condition improved, and no adverse reactions to omadacycline were observed. Potential adverse effects of omadacycline were evaluated, along with its utilization and dosage in children. Omadacycline has the potential to be a viable alternative anti-infective agent for the treatment of pediatric CAP in the absence of other drug options and with adequate safety evaluation and monitoring.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.